NSEAnalysts/Institutional Investor Meet/Con. Call Updates5d ago · 17 Jul 2026, 01:22 pm
Analysts/Institutional Investor Meet/Con. Call Updates
Dr. Lal Path Labs Ltd. · LALPATHLAB
✦ AI SummaryResults
Dr. Lal PathLabs Ltd. has informed the Exchange about Schedule of meet for Q1 FY27 earnings conference call on July 24, 2026.
Analysis Scores
Earnings Impact8/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk3/10
Liquidity Impact9/10
Market Sentiment6/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Dr. Lal Path Labs Ltd. has informed the Exchange about Schedule of meet
Attachments (1)
📄pdf
Download →
LALPATHLAB_17072026132245_concallintimation.pdf
View document text
July 17, 2026
National Stock Exchange of India Limited BSE Limited
Exchange Plaza, Corporate Relationship Department
Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers
Bandra Kurla Complex, Bandra (E) Dalal Street
Mumbai – 400 051 Mumbai – 400 001
Symbol: LALPATHLAB Scrip Code: 539524
Sub: Intimation of Conference Call for Investors/ Analysts for Q1 & FY27
Dear Sir/ Madam,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations 2015, please find attached the invite of the Conference Call for Investors/
Analysts to be held on Friday, July 24, 2026 at 5:30 P.M. (IST) to discuss the financial and
operating performance for Q1 & FY27.
We request you to please take the same on record.
Thanking You,
Yours Faithfully,
For Dr. Lal PathLabs Limited
Vinay Gujral
Company Secretary & Compliance Officer
Encl.: As above
Classification: Internal
Conference Call Invitation
Q1 FY27 Earnings Conference Call
Friday, July 24, 2026 at 5:30pm IST
Gurugram, July 17, 2026:
Dr. Lal PathLabs Ltd. (DLPL) will be hosting a conference call to discuss its Q1 FY27 results. DLPL
will be represented by (Hony) Brig. Dr. Arvind Lal – Executive Chairman, Mr. Shankha Banerjee –
Chief Executive Officer and Mr. Ved Prakash Goel – Group Chief Financial Officer & CEO –
International Business.
The conference call will be initiated with a brief discussion by the management on Q1 FY27 financial
and operating performance, which will be announced on the same day. Following this, there will be
an opportunity for participants to get their queries addressed during the call.
Details of the conference call are as follows:
Time ● 5:30pm IST on Friday, July 24, 2026
To enable participants to connect to the conference call without
having to wait for an operator, please register at the below
mentioned link.
Pre-registration
You will receive dial in numbers, passcode and a pin for the
concall on the registered email address provided by you. Kindly
dial into the call on the Conference Call date and use the
passcode & pin to connect to call.
● +91 22 6280 1141
Universal Access
● +91 22 7115 8042
● USA – 18667462133
● UK – 08081011573
Conference dial-in
International Toll Number ● Singapore – 8001012045
● Hong Kong – 800964448
-ENDS-
Regd. Office: Dr. Lal PathLabs Ltd., Block E, Sector-I8, Rohini, New Delhi – 110085, Tel: +91-11 4988 5050.
Corporate Office: Dr. Lal PathLabs Ltd., 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram - 122001, Haryana, Tel: +91-124-3016-500, Fax: +91-124-4234-468
E-mail: lalpathlabs@lalpathlabs.com, Web: www.lalpathlabs.com, CIN: L74899DL 1995PLC065388
About Dr. Lal PathLabs Limited (DLPL)
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic
services.
It has an integrated nationwide network, where patients and healthcare providers are offered a broad
range of diagnostic and related healthcare tests and services for use in core testing, patient
diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The
services of DLPL are aimed at individual patients, hospitals and other healthcare providers and
corporates. The catalogue of services includes 525 test panels, 3,130 pathology tests and 1,173
radiology and cardiology tests as on March 31, 2026.
As on March 31, 2026, DLPL’s has 312 clinical labs (including National Reference Lab at Delhi &
Regional Reference Lab at Kolkata, Bangalore & Mumbai), 7,727 Patient Service Centers (PSCs)
and 13,935 Pick-up Points (PUPs). In FY26 & FY25, DLPL collected and processed approximately
94.5 million samples and 85.6 million samples from 30.3 million and 28.8 million patients,
respectively.
Additional information on Dr. Lal PathLabs Limited:
Corporate Identification No: L74899DL1995PLC065388
Website: https://www.lalpathlabs.com/
For further information, please contact:
Ved P Goel Siddharth Rangnekar / Nishid Solanki
Dr. Lal PathLabs Limited CDR India
E-mail:ved.goel@lalpathlabs.com Email: siddharth@cdr-india.com
nishid@cdr-india.com
Disclaimer: Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such
forward-looking statements are subject to certain risks and uncertainties like Government actions, local political or economic
developments, technological risks, and many other factors that could cause our actual results to differ materially from those
contemplated by the relevant forward-looking statements. Dr. Lal PathLabs Limited will not be in any way responsible for any action
taken based on such statements and discussions and undertakes no obligation to publicly update these forward-looking statements to
reflect subsequent events or circumstances.
Regd. Office: Dr. Lal PathLabs Ltd., Block E, Sector-I8, Rohini, New Delhi – 110085, Tel: +91-11 4988 5050.
Corporate Office: Dr. Lal PathLabs Ltd., 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram - 122001, Haryana, Tel: +91-124-3016-500, Fax: +91-124-4234-468
E-mail: lalpathlabs@lalpathlabs.com, Web: www.lalpathlabs.com, CIN: L74899DL 1995PLC065388